| Optimized patients (n=32) | ||
|---|---|---|
| Age (years) | 47.2±10.6 | |
| Gender (%) Male/Female | 84.4/15.6 | |
| Disease duration (years) | 12.2±10.4 | |
| Baseline | Optimization time | |
| BASDAI (0–10) | 4.2±2,6 | 2.1±2.2 |
| BASFI (0-10) | 4±2.7 | 2.8±2.9 |
| ESR (mm/1° h) | 19±20.1 | 8.5±8.5 |
| CRP (mg/L) | 13.1±18.7 | 6.4±9.7 |
| Number of previous TNFi | 0.3±0.6 | |
| Current TNFi (%) | ||
| Infliximab | 31.3% | |
| Adalimumab | 21.9% | |
| Etanercept | 25% | |
| Golimumab | 21.9% | |